New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor

Hybridoma

Volumn 17, Issue 2, 1998, Pages 125-132

  Feng, X ^a   Pak, R H ^b   Kroger, L A ^a   Moran, J K ^b   DeNardo, D G ^a   Meares, C F ^b   DeNardo, G L ^b   DeNardo, S J ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Molecular Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; COPPER 1,4,8,11 TETRAAZACYCLOTETRADECANE N,N',N'',N''' TETRAACETIC ACID; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM 1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; ASCITES; BINDING AFFINITY; DIALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TARGETING; GENETIC ENGINEERING; HYBRIDOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL CULTURE;

ANIMALIA;

EID: 0031833527     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1998.17.125     Document Type: Article

References (38)

1. De Nardo SJ, DeNardo GL, Peng JS, and Colcher D: Monoclonal antibody radiopharmaceuticals for cancer radioimmunotherapy. In: Radioimmunoimaging and Radioimmunotherapy. Burchiel S, and Rhodes B (Eds.). Elsevier, New York, 1983, p. 409.
2. Bloomer WD, Lipstein R, and Dalton JF: Antibody-mediated radiotherapy. Cancer 1985;55:2229.
3. DeNardo SJ, Zhong G-R, Salako Q, Li M, DeNardo GL, and Meares CF: Pharmacokinetics of chimeric L6 conjugated to Indium-111 and Yttrium-90-DOTA-Peptide in tumor-bearing mice. J Nucl Med 1995;36:829-836.
4. Deshpande SV, DeNardo SJ, Meares CF, McCall MJ, Adams GP, and DeNardo GL: Copper-67-labeled monoclonal antibody Lym1. A potential radiopharmaceutical for cancer therapy: Labeling and biodistribution in Raji tumored mice. J Nucl Med 1988;29: 217-225.
5. Liu Y, Wu C: Radiolabeling of monoclonal antibodies with metal chelates. Pure Appl Chem 1991;63:427-463.
6. Meares CF, Moi MK, Diril H, Kukis DL, McCall MJ, Deshpande SV, DeNardo SJ, Snook D, and Epenetos AA: Macrocyclic chelates for radiometals for diagnosis and therapy. Br J Cancer 1990;62:21-26.
7. 111Indium-DOTA chelates: A simple and efficient method. Bioconjugate Chem 1994;5:101-104.
8. Kukis DL, Diril H, Greiner DP, DeNardo SJ, DeNardo GL, Salako QA, and Meares CF: A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer 1994;73:779-786.
9. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res 1995;55:5916S-5920S.
10. Begent RHJ, Bagshawe KD, Green AJ, Kelly AMB, Lane D, Glaser MG, Dewji MR, Baker TS, and Secher DS: Chimeric B72.3 antibody for repeated radioimmunotherapy of colorectal carcinoma. Eur J Cancer 1990;26:1008.
11. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, and Bendig MM: Reshaping a human antibody to inhibit the Interleukin 6-dependent tumor cell growth. Cancer Res 1993;53:851-856.
12. Gorman SD, Clark MR, Routledge EG, Cobbold SP, and Waldmann H: Reshaping a therapeutic CD4 antibody. Proc Natl Acad Sci USA 1991;88:4181-4185.
13. Cheetham J: Reshaping the antibody combining site by CDR replacement tailoring or tinkering to fit. Protein Eng 1988;2:170-172.
14. Bianchi E, Venturini S, Pessi A, Tramontano A, and Sollazzo M: High level expression and rational mutagenesis of a designed protein, the minibody: From an insoluble to a soluble molecule. J Mol Biol 1994;236:649-659.
15. Hu S-Z, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JYC, Shively JE, and Wu AM: Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-C-H3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56:3055-3061.
16. Tramontano A, Bianchi E, Venturini S, Martin F, Pessi A, and Sollazzo M: The making of the minibody: An engineered beta-protein for the display of conformationally constrained peptides. J Mol Recognit 1994;7:9-24.
17. Holliger P, Prospero T, and Winter G: Diabodies: Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993;90:6444-6448.
18. Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, and Weiner LM: In vitro and in vivo characterization of a human anti-c-erbB-2 single chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1995;1:73-81.
19. Michael NP, Chester KA, Melton RG, Robson L, Nicholas W, Boden JA, Pedley RB, Begent RHJ, Sherwood RF, and Minton NP: In vitro and in vivo characterization of a recombinant carboxypeptidase G-2:anti-CEA scFv fusion protein. Immunotechnology 1996;2:47-57.
20. 90Y radioimmunotherapy. Cancer Res 1994;54:5937-5946.
21. Rose LM, Gunasekara AH, DeNardo SJ, DeNardo GL, and Meares CF: Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 1996;43:26-30.
22. McCall MJ, Diril H, and Meares CF: Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjugate Chem 1990;1:222-226.
23. Penefsky HS; A centrifuged-column procedure for the measurement of ligand binding by beef heart fl. Meth Enzymol 1979;56:527-530.
24. Meares CF, McCall MJ, Reardon DT, Goodwin DA, Diamanti CI, and McTigue M: Conjugation of antibodies with bifunctional chelating agents: Isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 1984;142:68-78.
25. Harlow E, and Lane D: Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988.
26. Renn O, and Meares CF: Large-scale synthesis of the bifunctional chelating agent 2-(p-nitrobenzyl)-1, 4,7, 10-tetraazacyclododecan-N,N′,N″,N‴-tetraacetic acid, and the determination of its enantiomeric purity by chiral chromatography. Bioconjugate Chem 1992;3:563-569.
27. Moi MK, Meares CF, McCall MJ, Cole WC, and DeNardo SJ: Copper chelates as probes of biological systems: Stable copper complexes with a macrocyclic bifunctional chelating agent. Anal Biochem 1985;148:249-253.
28. DeNardo GL, Kroger LA, DeNardo SJ, Miers LA, Salako Q, Kukis DL, Fand I, Shen S, Renn O, and Meares CF: Comparative toxicity studies of yttrium-90 MX-DTPA and 2- IT-BAD conjugated monoclonal antibody (BrE-3). Cancer 1994;73:1012-1022.
29. Kukis DL, Diril H, Greiner DP, DeNardo SJ, DeNardo GL, Salako QA, and Meares CF: A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer 1994;73:779-786.
30. Steward MW, and Steensgaard J: Antibody Affinity: Thermodynamic Aspects and Biological Significance. CRC Press Inc., Boca Raton, FL, 1983.
31. Chang CA, Francesconi LC, Malley MF, Kumar K, Gougoutyas JZ, Tweedle MF, Lee DW, and Wilson LJ: Synthesis, characterization, and crystal structures of M(DO3A) (M = Fe, Gd) and Na[M(DOTA)] (M = Fe, Y, Gd). Inorg Chem 1993;32:3501-3508.
32. Reisen A, Zehnder M, and Kadan T: Metal complexes of macrocyclic ligands: Synthesis, properties, and structures of mononuclear complexes with 12- and 14-membered tetraazamacrocycle-N,N′,N″,N‴-tetraacetic acids. Helv Chim Acta 1986;69: 2067-2073.
33. Reardan DT, Meares CF, Goodwin DA, McTigue M, David GS, Stone MR, Leung JP, Bartholomew RM, and Frincke JM: Antibodies against metal chelates. Nature (London) 1985;316:265-268.
34. LeDoussal JM, Martin M, Gautherot E, Delaage M, and Barbet J: In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: Enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989;30:1356-1366.
35. Schuhmacher J, Klivenyi G, Matys R, Stadler M, Regiert T, Hauser H, Doll J, Maier-Borst W, and Zoller M: Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography. Cancer Res 1995;55:115-123.
36. Hnatowich DJ, Virzi F, and Rusckowski M: Investigations of avidin and biotin for imaging applications. J Nucl Med 1987;28: 1294-1302.
37. Paganelli G, Belloni C, Magnani P, Zito F, Pasini A, Sassi I, Meroni M, Mariani M, Vignali M, and Siccardi AG: Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med 1992;19:322-329.
38. Bos ES, Kuijpers WH, Meesters-Winters M, Pham DT, deHaan AS, vanDoornmalen AM, Kaspersen FM, van Boeckel CA, and Gourgeon-Bertrand F: In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer. Cancer Res 1994;54:3479-3486.